Medivir licenses antiviral compound MIV-606 to Epiphany

By E. Janene Geiss

Philadelphia, Sept. 8 - Medivir AB and Epiphany Biosciences announced Friday the signing of a license agreement on MIV-606 (valomaciclovir), Medivir's phase 2 compound with potent activity against varicella zoster virus and other viruses.

Under the agreement, Medivir, a Huddinge, Sweden-based pharmaceutical company, said it will receive equity in Epiphany, milestone payments of up to $24.5 million and royalties from worldwide sales except the Nordic countries where Medivir has retained the marketing rights for all disease indications.

San Francisco-based Epiphany will be responsible for the further clinical development of MIV-606.

Phase 2a studies have shown MIV-606 to be efficacious and safe in patients with shingles, caused by the varicella zoster virus. MIV-606 also is a potent inhibitor of other herpes viruses increasingly implicated in various diseases such as mononucleosis, chronic fatigue syndrome, multiple sclerosis and the development of HIV/AIDS.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.